BioCryst Pharmaceuticals, Inc. Q3 2026 Earnings Recap

BioCryst shares fell 3.9% after earnings, with the likely concern that the quarter’s revenue included an upper-teens-of-millions contribution from CareMed’s one-time inventory build, making reported growth less representative of underlying demand. The company said ORLADEYO revenue excluding Europe still grew year over year after removing that benefit, but future revenue should more closely reflect patient demand.

Key Takeaways

• Net revenue was $174.8 million in the quarter, with more than 95% from the U.S. business.
• ORLADEYO revenue excluding Europe increased 20% year over year on a comparable basis; the CareMed inventory build contributed an upper-teens-of-millions amount to quarterly revenue.
• CareMed’s inventory is expected to remain near the lower end of its typical 1-to-3-week range, limiting that transition-related revenue contribution going forward. BioCryst said days to first shipment for new patients are already improving.
• Management reported continued growth in treated patients and new prescribers, and said early uptake of ORLADEYO pellets in children has been promising.
• Navenibart’s pivotal trial fully enrolled in June, with 12-month top-line data still expected in the third quarter of next year; early BCX1777 data are expected by year-end.